At the 2019 ELCC meeting, Boehringer Ingelheim hosted a symposium and presented recent findings in the treatment of lung cancer.
At this symposium, a faculty of renowned experts discussed sequential therapy in EGFR mutation-positive NSCLC and in non-oncogene-addicted non-squamous NSCLC. Please see below for video interviews with the faculty and downloads of their presentations.
Publications on our emerging data and the investigator-initiated VARGADO study were also presented at ELCC.
Find out more about other oncology events
Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.
*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.
© 2019 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: June 2019